[{"id":"6575bade-72bb-495f-8e06-eb39a449767d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639508","created_at":"2021-01-17T17:26:36.480Z","updated_at":"2024-07-02T16:35:44.723Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","source_id_and_acronym":"NCT01639508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" RET • ROS1 • KIF5B • AXL • NTRK","pipe":" | ","alterations":" RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion","tags":["RET • ROS1 • KIF5B • AXL • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-06-26"},{"id":"20b63c84-5fbb-4f76-a357-de7569544623","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922583","created_at":"2021-01-18T08:40:42.278Z","updated_at":"2024-07-02T16:37:08.883Z","phase":"Phase 2","brief_title":"AUY922 in Patient With Stage IV NSCLC","source_id_and_acronym":"NCT01922583","lead_sponsor":"National Taiwan University Hospital","biomarkers":" EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation","tags":["EGFR • HER-2 • BRAF • ALK • RET • ROS1 • EML4 • KIF5B • SLC34A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • ALK positive • EGFR T790M • RET fusion • EGFR exon 20 insertion • ALK rearrangement • HER-2 exon 20 insertion • ALK fusion • RET mutation • KIF5B-RET fusion • ALK translocation • EGFR exon 20 mutation • BRAF D594G • BRAF G469A • EGFR A767_V769dup • HER-2 YVMA • TFG-ALK fusion • BRAF exon 15 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2018-07-18"}]